Skip to main content
Motor Neuron Disease Models

ALS Mouse Models

Since 1998, ingenious targeting laboratory has supported amyotrophic lateral sclerosis research with custom mouse models enabling mechanistic studies of motor neuron degeneration, evaluation of neuroprotective strategies, and preclinical testing of disease modifying therapeutics.

ALS mouse models provide essential platforms for investigating the molecular pathways underlying motor neuron death, testing hypotheses about protein aggregation and RNA metabolism, and developing therapies targeting SOD1, TDP43, FUS, C9orf72, and other genetically validated targets.

2,500+
Projects Completed
800+
Publications
26+
Years Experience
100%
Success Rate

Genetic Basis of ALS

Amyotrophic lateral sclerosis is characterized by progressive degeneration of upper and lower motor neurons, leading to muscle weakness, paralysis, and death typically within 3 to 5 years of diagnosis. While most cases are sporadic, approximately 10% are familial with identifiable genetic causes.

Major ALS Genes

SOD1 (Superoxide Dismutase 1)

The first ALS gene identified, with over 180 known mutations. SOD1 mutations cause disease through toxic gain of function rather than loss of enzyme activity. The G93A mutation is the most commonly studied in mouse models.

TARDBP (TDP43)

TDP43 pathology is present in approximately 97% of ALS cases, making it a central player in disease pathogenesis. Mutations cause both familial ALS and frontotemporal dementia.

FUS (Fused in Sarcoma)

Like TDP43, FUS is an RNA binding protein whose mutations cause ALS and FTD. FUS mutations lead to cytoplasmic aggregation and nuclear depletion.

C9orf72

Hexanucleotide repeat expansion in C9orf72 is the most common genetic cause of both ALS and FTD. Disease mechanisms include loss of C9orf72 function, toxic RNA foci, and dipeptide repeat protein toxicity.

Additional ALS Genes

OPTN, TBK1, SQSTM1: Autophagy pathway genes
VCP: Protein quality control
PFN1: Cytoskeleton dynamics
UBQLN2: Protein degradation
CHCHD10: Mitochondrial function

SOD1 Models

SOD1 transgenic mice remain the most widely used ALS models, enabling therapeutic testing and mechanistic studies of motor neuron degeneration.

Model TypeFeaturesApplications
SOD1 G93A TransgenicHigh copy number, aggressive diseaseParalysis onset ~90 days, therapeutic testing
SOD1 G85RAlternative mutation, slower progressionLonger therapeutic window studies
SOD1 KnockinPhysiological expression levelsAvoids overexpression artifacts
SOD1 KnockoutNull alleleAge dependent motor neuron loss studies

TDP43 Models

TDP43 models address the most common ALS pathology, with TDP43 mislocalization from nucleus to cytoplasm being a pathological hallmark.

Model TypeFeaturesApplications
TDP43 A315T KnockinPatient derived mutation, endogenous controlDisease modeling without overexpression
TDP43 Q331K KnockinAge dependent motor phenotypesProgressive TDP43 pathology
Conditional TDP43Cre dependent expression or deletionCell type specific studies
TDP43 KnockoutConditional in motor neuronsProgressive motor phenotypes

Cell Type Specific Approaches

ALS involves both motor neurons and surrounding glia. Cell type specific gene manipulation reveals distinct contributions to disease.

Motor Neuron Specific

ChAT Cre or VAChT Cre

Reveals cell autonomous disease mechanisms

Astrocyte Specific

GFAP Cre or Aldh1l1 Cre

Demonstrates non cell autonomous toxicity

Microglial Specific

CX3CR1 Cre

Studies microglial contribution to disease progression

Oligodendrocyte Specific

Mog Cre or CNP Cre

Investigates oligodendrocyte dysfunction

Phenotyping ALS Models

Motor Function Assessment

Rotarod

Motor coordination and balance. Decline in latency to fall correlates with disease progression.

Grip Strength

Forelimb and hindlimb grip strength measurement provides quantitative muscle function assessment.

Gait Analysis

Stride length, cadence, and stance time reveal motor deficits before paralysis onset.

Hanging Wire

Neuromuscular function assessment. Time to fall from inverted grid.

Neuropathology Endpoints

  • Motor neuron counts: Stereological quantification of ChAT positive neurons in spinal cord ventral horn
  • Neuromuscular junction analysis: Innervation status of neuromuscular junctions in hindlimb muscles
  • Protein aggregation: Immunohistochemistry for mislocalized TDP43, SOD1 aggregates, or dipeptide repeat proteins
  • Gliosis: Astrocyte (GFAP) and microglial (Iba1) activation in spinal cord

Selected Publications in ALS Research

Recent publications demonstrate the utility of genetically engineered mouse models in ALS research:

What Researchers Say

ingenious Targeting Laboratory is highly recommended for generating custom animal models. Past 2 years, we have made 2 conditional knockout mouse lines. All processes of each project were scientifically and professionally handled. Their scientific consulting to initiate the project was superb compared to other companies, and transparency of the project progress reported by project managers was excellent. Their excellency and dedication to meet our needs in a timely manner are invaluable to continuation of our research progress.

Hyekyung Plumley, PhD

Warren Center for Neuroscience Drug Discovery

✦ New for 2026

Breeding Scheme Architect

Plan complex multi-allele breeding strategies, calculate expected genotype ratios, and estimate time to experimental cohorts—all before starting your project.

Visualize multi-generation breeding paths
Calculate Mendelian ratios automatically
Estimate timeline to study-ready cohorts

Free Research Tool

No account required

Allele 1Gene-flox (conditional)
Allele 2Cre-driver (tissue-specific)
TargetHomozygous knockout

→ 3 generations to target genotype

Start Your ALS Model Project

Our scientific consultants are ready to discuss your ALS research requirements and recommend the optimal model design for your program. Initial consultation is provided at no charge and includes target analysis, model strategy recommendations, and timeline estimates.

Frequently Asked Questions

Common ALS mutations include SOD1 mutations (A4V, G93A, G37R, etc.), TDP43 mutations (A315T, M337V, Q331K, etc.), FUS mutations, and C9orf72 repeat expansions. Point mutation knockins can introduce any specific human mutation for disease modeling at physiological levels.

Standard motor assessments include rotarod (motor coordination), grip strength (forelimb and hindlimb), gait analysis (stride length, cadence), and hanging wire test (neuromuscular function). Survival is typically the primary endpoint, defined by inability to right within 30 seconds or more than 20% body weight loss.

Yes. Conditional expression of ALS mutations (e.g., Cre dependent TDP43 or FUS mutations) enables spatial and temporal control, allowing study of motor neuron specific effects or adult onset disease. This can avoid developmental defects and better model sporadic ALS versus familial ALS.

Disease progression varies by mutation and model. SOD1 G93A transgenic mice show symptom onset around 90 to 100 days with rapid progression. TDP43 models may show slower progression. Knockin models at physiological expression levels typically show slower, more gradual progression than transgenic models.

C57BL/6 is most commonly used for ALS models due to extensive characterization and behavioral baseline data. Strain background can significantly affect disease progression and survival, so maintaining consistent backgrounds is important for reproducible experiments and comparison with published data.

Lab Signals

Stay Current on ALS Research

Subscribe to Lab Signals for the latest motor neuron disease model updates and research insights.

Subscribe Free